Farooqui & Farooqui, Securities Litigation Partners LLP James (Josh) Wilson He encourages investors who have incurred losses exceeding $75,000 at Basera to contact him directly to discuss their options
If you suffer losses exceeding $75,000 Pacera Between August 2, 2023 and August 8, 2024 If you would like to discuss your legal rights, contact Farooqui & Farooqui Partner Josh Wilson live in 877-247-4292 or 212-983-9330 (ext. 1310).
(You can also click here for additional information)
New York, New York–(Newsfile Corp. – January 19, 2025) – Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Pacira BioSciences, Inc. (“Pacira” or the “Company”) (NASDAQ: PCRX) and reminds investors of March 14, 2025 deadline For the role of lead plaintiff in a federal securities class action lawsuit filed against the Company.
Farooqui & Farooqui is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The company has recovered hundreds of millions of dollars for investors since its founding in 1995. See www.faruqilaw.com.
According to the complaint, on August 9, 2024, Pacera announced that a New Jersey district court had invalidated its '495 patent, holding that eVenus had not infringed the '495 patent on the basis of obviousness and foresight. The complaint alleges that this ruling came shortly after Basera submitted additional evidence to the court, which the court stated would have no impact on the basis on which the decision was based. The complaint also alleges that this ruling was secondary to the court's own ruling affecting the construction of claims for both Pacira's '495 and '336 patents for eVenus.
According to the complaint, Pacira's announcement that its 495 patent was invalidated caught investors and analysts alike by surprise as they immediately reacted to the revelations. The complaint alleges that the price of Pacira's common stock declined significantly. According to the complaint, from a closing market price of $22.36 per share on August 8, 2024, Pacira's stock price fell to a low of $11.70 per share on August 9, 2024, a decline of more than 47% in one day, damaging Investors.
A court-appointed lead plaintiff is the investor with the greatest financial interest in the relief sought by the class and is appropriate and typical for members of the class who direct and oversee litigation on behalf of the putative class. Any member of the putative class may ask the court to serve as lead plaintiff through counsel of their choice, or they may choose to do nothing and remain an absent member of the class. Your ability to participate in any recovery is not affected by the decision whether or not to serve as lead plaintiff.
Faruqi & Faruqi, LLP also encourages anyone with information regarding Pacira's conduct to contact the firm, including whistleblowers, former employees, shareholders and others.
Follow us for updates on LinkedIn, X, or Facebook (NASDAQ:).
Lawyer advertisement. The law firm responsible for this announcement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Past results do not guarantee or predict a similar result with respect to any future matter. We welcome the opportunity to discuss your specific case. All communications will be treated confidentially.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/237458
